---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-063475"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:45:46.827425+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital

## Summary
- New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.
- Fixed purchases per notice capped at lower of 10,000 shares or $100,000; VWAP purchases aggregate limit of $10M.
- Beneficial ownership limitation of 4.99% per purchase.
- Registration Rights Agreement filed concurrently for shares issued.
- Replaces prior equity lines from Feb '24 and Nov '24 which had raised ~$7.5M combined.

## SEC filing metadata
- accession: 0001213900-25-063475
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025063475/0001213900-25-063475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025063475/ea0248789-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-063475
- JSON: https://secwatch.observer/filing/0001213900-25-063475.json
- Plain text: https://secwatch.observer/filing/0001213900-25-063475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.